1. Metabolic Disease

Metabolic Disease

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Metabolic Disease Related Products (345):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10182
    CHIR-99021 252917-06-9
    CHIR-99021 is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; > 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases.
  • HY-13443
    Exendin-4 141758-74-9
    Exendin-4(Exenatide), a 39 amino acid peptide, activates GLP-1 (glucagon-like peptide-1) receptors to increase intracellular cAMP in pancreatic acinar cells and has no effect on VIP receptors.
  • HY-17386
    Rosiglitazone 122320-73-4
    Rosiglitazone is a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist, and is a blocker of TRPM2 and TRPM3 channels.
  • HY-50108
    GW 4064 278779-30-9
    GW 4064 is a potent FXR agonist with EC50 of 65 nM.
    GW 4064
  • HY-50202
    Etomoxir 124083-20-1
    Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1).
  • HY-50202A
    (R)-(+)-Etomoxir sodium salt 828934-41-4
    (R)-(+)-Etomoxir sodium salt is R-form of Etomoxir sodium salt. Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1).
    (R)-(+)-Etomoxir sodium salt
  • HY-14601
    Pioglitazone hydrochloride 112529-15-4
    Pioglitazone hydrochloride is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
    Pioglitazone hydrochloride
  • HY-15848
    AdipoRon 924416-43-3
    AdipoRon is a novel AdipoR agonist, binding to both AdipoR1 (Kd=1.8 μM) and AdipoR2 (Kd=3.1 μM).
  • HY-B0131
    Prostaglandin E1 745-65-3
    Prostaglandin E1 (Alprostadil) is a prostaglandin, which is used in the treatment of erectile dysfunction and has vasodilatory properties.
    Prostaglandin E1
  • HY-10450
    Dapagliflozin 461432-26-8
    Dapagliflozin is a new pharmacological therapy for type 2 diabetes, and inhibits sodium/glucose cotransporter 2 (SGLT2), which results in excretion of glucose into the urine.
  • HY-N0504
    Lovastatin 75330-75-5
    Lovastatin is an inhibitor of HMG-CoA reductase with IC50 of 3.4 nM, used for lowering cholesterol (hypolipidemic agent).
  • HY-15409
    Empagliflozin 864070-44-0
    Empagliflozin is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for hSGLT-2.
  • HY-14832
    PTC124 775304-57-9
    PTC124 targets nonsense mutations, which insert a termination codon in the middle of the CFTR gene.
  • HY-10451
    Canagliflozin 842133-18-0
    Canagliflozin is a selective SGLT2 inhibitor with IC50 of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
  • HY-15145
    SRT 1720 Hydrochloride 1001645-58-4
    SRT 1720 (Hydrochloride) is a selective activator of human SIRT1 (EC1.5=0.16 μM) versus the closest sirtuin homologues, SIRT2 and SIRT3 (SIRT2: EC1.5=37 μM; SIRT3: EC1.5 > 300 μM).
    SRT 1720 Hydrochloride
  • HY-10838
    GW 501516 317318-70-0
    GW501516(GSK-516; GW1516) is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ.
    GW 501516
  • HY-10007
    NPS-2143 284035-33-2
    NPS-2143 is a novel potent and selective antagonist of Ca2+ receptor with IC50 of 43 nM.
  • HY-A0190
    Ceruletide 17650-98-5
    Ceruletide (Caerulein) is a biologically active decapeptide isolated from the skin of the Australian frog Hyla caerulea. It is a potent cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts in humans and
  • HY-15304
    Dynasore 304448-55-3
    Dynasore is a cell-permeable small molecule that inhibits the GTPase activity of dynamin1, dynamin2 and Drp1, the mitochondrial dynamin.
  • HY-14823
    Sobetirome 211110-63-3
    Sobetirome is a thyroid hormone receptor β (TRβ)-specific agonist, GC-1 is designed to bind selectively to TRβ-1 with EC50 of 0.16 μM.